Oculis’ Privosegtor Receives U.S. FDA Breakthrough Therapy Designation for Optic Neuritis Treatment

Oculis Holding AG, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its investigational drug Privosegtor for the treatment of optic neuritis, a serious neuro‑ophthalmic condition that can lead to permanent vision loss. Privosegtor is a novel peptoid small molecule designed to penetrate both the blood–brain and retinal barriers, positioning it as a potential first‑of‑its‑kind neuroprotective therapy for optic neuropathies with no currently approved neuroprotective treatments available. The FDA decision is supported by results from the Phase 2 ACUITY trial, where patients treated with Privosegtor plus standard IV steroids saw an average gain of 18 letters on a low contrast visual acuity chart after three months compared with placebo, an improvement considered clinically meaningful for daily visual function. The treatment also showed preservation of retinal and optic nerve structure and reduction in biomarkers associated with neuroaxonal injury. Following a 2025 meeting with the FDA, Oculis launched its PIONEER program, a global development initiative encompassing three pivotal trials for Privosegtor in optic neuritis and non‑arteritic anterior ischemic optic neuropathy (NAION), representing a potential U.S. market exceeding $7 billion. The first of these trials has already begun site activation with enrollment expected soon. Leaders from Oculis and neuro‑ophthalmology experts highlighted the groundbreaking data and significant unmet need in conditions like optic neuritis, which often affects young adults and can be an early sign of multiple sclerosis. #Oculis #Privosegtor #OpticNeuritis #FDABreakthroughTherapy #SlimScan #GrowthStocks #CANSLIM